Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 4 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 5 | Y018398 | — |
No adverse effects were reported; the second extra dose (dose number 5) was on 3/4/2025; The first extra dose (dose number 4) was on 6/2/2023; This spontaneous report was received from a nurse concerning a 20-year-old female patient. The patient's medical history, concurrent conditions, concomitant therapies and drug reactions/allergies were not reported. On an unspecified date in approximately 2020, when she was 17-year-old, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) dose number 1, 1 dosage form (route of administration, anatomical location, lot # and expiration date were not reported). On unspecified dates, she received the doses 2 and 3 of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), 1 dosage form each (route of administration, anatomical location, lot # and expiration date were not reported), completing the vaccination series. Then, on 06-Feb-2023, the patient was administered a 4th dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), 1 dosage form (route of administration, anatomical location, lot # and expiration date were not reported) (extra dose administered). Additionally, on 04-Mar-2025, the patient received another dose of Human Papillomavirus 9-valent Vaccine, Recombinant, lot #Y018398, expiration date: 04-Nov-2026, dose number 5, 0.5 mL administered by a health professional (route of administration and anatomical location were not reported) (extra dose administered). All vaccine doses were administered as prophylaxis. It was also reported that patient did not recall her administration history, when she consented to the Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) series again on 06-Feb-2023. No adverse effects were reported (no adverse event.) Additional lot #s are being requested and will be submitted if received.